COM_RESEARCHSTUDIES_DETAIL_AVAL_STATUS_4

A Study of ALX148 With Enfortumab Vedotin for Subjects With Urothelial Carcinoma ASPEN-07

To evaluate the safety and tolerability of ALX148 in combination with enfortumab vedotin in subjects with previously treated locally advanced or metastatic urothelial carcinoma. To determine the maximum tolerated dose (MTD) and the recommended Phase 2 dose (RP2D) of ALX148 in combination with enfortumab vedotin.

Age & Gender

18 years ~ 99 years
Male, Female

Contact the Team

Location

COM_RESEARCHSTUDIES_DETAIL_HEADER_BASIC_CONTACT_4

North Carolina

Additional Study Information

Principal Investigator

Matthew Milowsky
Medicine- Oncology

Study Type

Clinical or Medical
Interventional

Study Topics

Cancer (Other Cancers)
Urinary and Bladder

IRB Number

22-2399

ClinicalTrials.gov

NCT05524545

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Helpful Links

Questions?

This email address is being protected from spambots. You need JavaScript enabled to view it.